LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Analysis of therapy monitoring in the International Congenital Adrenal Hyperplasia Registry.

Lawrence, Neil / Bacila, Irina / Dawson, Jeremy / Bryce, Jillian / Ali, Salma R / van den Akker, Erica L T / Bachega, Tânia A S S / Baronio, Federico / Birkebaek, Niels H / Bonfig, Walter / van der Grinten, Hedi C / Costa, Eduardo C / de Vries, Liat / Elsedfy, Heba / Güven, Ayla / Hannema, Sabine / Iotova, Violeta / van der Kamp, Hetty J / Clemente, María /
Lichiardopol, Corina R / Milenkovic, Tatjana / Neumann, Uta / Nordenström, Ana / Poyrazoğlu, Şukran / Probst-Scheidegger, Ursina / De Sanctis, Luisa / Tadokoro-Cuccaro, Rieko / Thankamony, Ajay / Vieites, Ana / Yavaş, Zehra / Faisal Ahmed, Syed / Krone, Nils

Clinical endocrinology

2022  Volume 97, Issue 5, Page(s) 551–561

Abstract: Objective: Congenital adrenal hyperplasia (CAH) requires exogenous steroid replacement. Treatment is commonly monitored by measuring 17-OH progesterone (17OHP) and androstenedione (D4).: Design: Retrospective cohort study using real-world data to ... ...

Abstract Objective: Congenital adrenal hyperplasia (CAH) requires exogenous steroid replacement. Treatment is commonly monitored by measuring 17-OH progesterone (17OHP) and androstenedione (D4).
Design: Retrospective cohort study using real-world data to evaluate 17OHP and D4 in relation to hydrocortisone (HC) dose in CAH patients treated in 14 countries.
Patients: Pseudonymized data from children with 21-hydroxylase deficiency (21OHD) recorded in the International CAH Registry.
Measurements: Assessments between January 2000 and October 2020 in patients prescribed HC were reviewed to summarise biomarkers 17OHP and D4 and HC dose. Longitudinal assessment of measures was carried out using linear mixed-effects models (LMEM).
Results: Cohort of 345 patients, 52.2% female, median age 4.3 years (interquartile range: 3.1-9.2) were taking a median 11.3 mg/m
Discussion: Registry data show large variability in 17OHP and D4 between centres. 17OHP correlates with D4 well when accounting for age. Prescribed HC dose per body surface area decreased with weight gain.
MeSH term(s) 17-alpha-Hydroxyprogesterone ; Adrenal Hyperplasia, Congenital/drug therapy ; Androstenedione ; Child ; Child, Preschool ; Female ; Humans ; Hydrocortisone/therapeutic use ; Male ; Progesterone ; Registries ; Retrospective Studies
Chemical Substances Androstenedione (409J2J96VR) ; Progesterone (4G7DS2Q64Y) ; 17-alpha-Hydroxyprogesterone (68-96-2) ; Hydrocortisone (WI4X0X7BPJ)
Language English
Publishing date 2022-07-11
Publishing country England
Document type Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID 121745-8
ISSN 1365-2265 ; 0300-0664
ISSN (online) 1365-2265
ISSN 0300-0664
DOI 10.1111/cen.14796
Shelf mark
Zs.A 814: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top